Literature DB >> 14747244

Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic?

David L Schriger1, Brett Lorber.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 14747244     DOI： 10.2337/diacare.27.2.592

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  14 in total

1.  Comment on: Godsland IF, Jeffs JAR, Johnston DG (2004) Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47:1157-1166.

Authors:  C Ionescu-Tîrgovişte
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

2.  New Zealand cardiovascular guidelines: best practice evidence-based guideline: the assessment and management of cardiovascular risk December 2003.

Authors:  Michael Crooke
Journal:  Clin Biochem Rev       Date:  2007-02

3.  Examination of the fasting and 2-h plasma glucose in the light of impairment in beta-cell function: what does the epidemiological data tell us?

Authors:  Suhail A R Doi; Glenn M Ward
Journal:  Endocrine       Date:  2014-06-01       Impact factor: 3.633

4.  A prospective study of fasting plasma glucose and risk of stroke in asymptomatic men.

Authors:  Xuemei Sui; Carl J Lavie; Steven P Hooker; Duck-Chul Lee; Natalie Colabianchi; Chong-Do Lee; Steven N Blair
Journal:  Mayo Clin Proc       Date:  2011-09-12       Impact factor: 7.616

5.  Nitric oxide synthase 3 deficiency limits adverse ventricular remodeling after pressure overload in insulin resistance.

Authors:  Baptiste Kurtz; Helene B Thibault; Michael J Raher; John R Popovich; Sharon Cawley; Dmitriy N Atochin; Sarah Hayton; Hannah R Shakartzi; Paul L Huang; Kenneth D Bloch; Emmanuel Buys; Marielle Scherrer-Crosbie
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-19       Impact factor: 4.733

6.  Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart.

Authors:  M Bartnik; L Rydén; K Malmberg; J Ohrvik; K Pyörälä; E Standl; R Ferrari; M Simoons; J Soler-Soler
Journal:  Heart       Date:  2006-08-11       Impact factor: 5.994

7.  Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose.

Authors:  Samuel Dagogo-Jack; Hasan Askari; Gunjan Tykodi
Journal:  J Clin Endocrinol Metab       Date:  2009-03-10       Impact factor: 5.958

8.  Prevalence of cardiometabolic risk factors by weight status in a population-based sample of Quebec children and adolescents.

Authors:  Marie Lambert; Edgard E Delvin; Emile Levy; Jennifer O'Loughlin; Gilles Paradis; Tracie Barnett; Jennifer J McGrath
Journal:  Can J Cardiol       Date:  2008-07       Impact factor: 5.223

9.  Normal fasting plasma glucose and risk of prediabetes and type 2 diabetes: the Isfahan Diabetes Prevention Study.

Authors:  Mohsen Janghorbani; Masoud Amini
Journal:  Rev Diabet Stud       Date:  2012-02-10

10.  The effect of lowering the threshold for diagnosis of impaired fasting glucose.

Authors:  So Hun Kim; Wan Sub Shim; Eun A Kim; Eun Joo Kim; Seung Hee Lee; Seong Bin Hong; Yong Seong Kim; Shin Goo Park; Jong Han Leem; Jong Whan Lim; Hun-Jae Lee; Moonsuk Nam
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.